• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Robert Gabbay on the Intersection of COVID-19 and Diabetes

Video

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, shares his thoughts on long COVID-19 among those with type 2 diabetes and the rise of new-onset cases of type 1 diabetes throughout the pandemic.

Early data showing that type 2 diabetes may be a risk factor for long COVID-19 are very concerning, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.


Transcript

Research shows type 2 diabetes may influence the likelihood of developing long COVID-19. What are your thoughts on this and have you seen it occur?

Long COVID-19 is really yet one more concerning aspect of the pandemic. We are seeing more and more cases. I certainly have had, in my practice, I see patients that continue to have a variety of constellation of symptoms. Sometimes that's hard to sort out, was that related to COVID-19 or people develop other conditions? And [the] temporal relationship often has people considering that that’s related to their COVID-19 infection. There is some early data suggesting that type 2 diabetes may be one of the risk factors for long COVID-19, and that’s very concerning.

Several studies have documented a rise in type 1 diabetes during the pandemic. What do you think accounts for this?

The American Diabetes Association funded a series of research grants as the pandemic was beginning, and a couple of those projects were looking at the ability of COVID-19 virus to infect beta cells. It may be that by direct attacking the beta cells, insulin-producing cells, that is leading to the development of type 1 diabetes, because there was a recent CDC report that followed other reports that have been out there of new cases of type 1 diabetes developing in children as a result of COVID-19 infection.

Related Videos
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
"Integrating New PAH Therapies into Clinical Practice"
Julie Patterson, PharmD, PhD
"Clinical Evidence for Emerging PAH Therapies"
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Dr Chris Pagnani
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.